Mriglobal

“Governing body and management the governing body has delegated authority to act on its behalf to an executive committee. The executive committee may exercise any and all powers of the board of directors subject to the paramount power of the board. The executive committee may convene between board meetings to make decisions that cannot be delayed until the next board meeting. The executive committee members are all voting directors. Specifically, the executive committee is comprised of the chair of the board, vice chairs of the board, chair of the finance and audit committee, chair of the nominating and governance committee, chair of the compensation and hr committee, chair of the science and technology committee, and the most recent past chair of the board of directors, so long as he or she is still a member of the board of directors.”

“Business and family relationships malcom m. Aslin and stephen gound have a business relationship.”

“Review of 990 prior to filing the 990 is reviewed by mriglobal staff, including the cfo, controller, and general counsel. A final draft version is also reviewed by mriglobal's finance and audit committee. Each member of the board of directors receives a final draft version of the 990 prior to the applicable board of directors' meeting. Any updates resulting from the review by the finance and audit committee are presented to the board of directors at this meeting.”

“Monitoring and enforcement of board independence the officers, directors, trustees and key employees of mriglobal are required to complete a disclosure statement on an annual basis. The disclosures set forth on the statements are presented to the finance and audit committee of the mriglobal board of directors by the mriglobal compliance officer. The finance and audit committee discusses the disclosure statements to determine if any potential conflict of interest situations exist with respect to the officers, directors, trustees and key employees of mriglobal. At the following mriglobal board meeting, an executive summary of the disclosure statements is presented to the directors and the finance and audit committee reports the outcome of its discussion to the directors. The directors are presented the opportunity to discuss the finance and audit committee's findings or any other potential conflict of interest issues presented in the executive summary. Ultimately, the board of directors will determine whether a conflict of interest exists with respect to any officer, director, trustee or key employee of mriglobal. The finance and audit committee's findings and the directors' discussion of potential conflict of interest situations are recorded in the minutes of the board meeting, including determination of whether a conflict of interest exists, the names of the individuals involved, the nature of the potential conflict, the action taken and the basis on which the board reached its decision. Mriglobal has certain procedures with respect to addressing a conflict of interest transaction. Any action to be taken by mriglobal involving or pertaining to an individual, entity or circumstance with respect to which an officer, director, trustee or key employee (each, a covered person) has a conflicting interest will be discussed and voted on by the board of directors. The covered person will leave the meeting during the discussion of, and the vote on, the transaction or arrangement that may result in a conflict of interest. In considering any such action to be taken, the board will undertake appropriate due diligence and inform itself of all material information reasonably available to it and explore all reasonable alternatives to the proposed action that would not involve the conflict of interest. The standard for the determination of whether to undertake the proposed action is whether such action is, based on a reasonable good-faith belief, (i) in mriglobal's best interest, (ii) for its own benefit, and (iii) fair and reasonable to mriglobal. The board will document whether or not the conflict of interest transaction was approved, the names of the persons present for the discussion and vote, the content of the discussion, whether alternatives were discussed that did not involve a conflict of interest, the basis for the determination that the transaction was (i) in mriglobal's best interest, (ii) for its own benefit, and (iii) fair and reasonable to mriglobal, and the record of the vote taken with respect to who voted to approve the transaction. If the board has reasonable cause to believe that a covered person has failed to disclose a conflict of interest situation, it will afford the covered person an opportunity to explain the alleged failure to disclose. If, after hearing the response of the covered person and making such further investigation as may be warranted under the circumstances, the board determines that the covered person has in fact failed to disclose a conflict of interest situation, it will take appropriate corrective action. The mriglobal conflict of interest policy requires that the officers, directors, trustees and employees of mriglobal disclose any potential conflict of interest situation to the appropriate party, including an employee's supervisor, a representative of human resources, the compliance officer, the board of directors or the mriglobal ethics hotline, upon awareness that a conflict of interest may exist.”

“Compensation of officers, directors, key employees mriglobal's compensation & hr committee (committee) of the board of directors is responsible for reviewing and approving executive compensation in all areas. On an annual basis, the committee reviews and approves compensation for executive officers of the institute. The committee reviews and approves the ceo's performance evaluations and compensation recommendations for the executives. The committee is informed of summary data on the institute's employee population (e.g. Total personnel costs, employee diversity, turnover, etc.). The committee utilizes compensation survey data, provided by an outside party, to benchmark compensation against similarly-situated companies. The committee's minutes document the decisions and basis used for mriglobal's executive compensation.”

“Governing documents, conflict of interest policy, financial statements mriglobal's governing documents and financial statements are made available to the public upon request. Mriglobal's conflict of interest policy is not made available to the public.”

“Defense and infrastructure (d&i): d&i is mriglobal's largest line of business. D&i is primarily involved in research and development, engineering, program management and operations in the areas of national security and defense, energy, and transportation. The us government funds more than 96% of project work performed doing applied research and development, testing and evaluation. D&i supports field monitoring and forensics analysis programs in support of chemical, biological, radiological, nuclear, and explosives (cbrne) missions. D&i conducts a number of systems engineering and integration programs that target the development of national security technologies that include mobile laboratory analytical systems, chemical containment systems, robotics systems and chemical sensors. D&i also conducts bio-surveillance, biosafety and biosecurity programs for the us government. D&i's work depends on mriglobal's ability to work with regulated substances requiring high levels of oversight and certification. D&i's transportation programs support the federal highway administration and state highway agencies. Mriglobal's energy programs focus on technology assessments for both fossil and renewable energy sources and are conducted for us government and commercial customers.”

“Global health & security (ghs): the ghs line of business is primarily involved in research and development in product development, repository management, diagnostics, medical countermeasures, pharmaceutical and vaccine development, and agriculture and food safety. The largest client sector is the us government for which more than 80% of the work is conducted. Ghs performs studies that target the development of therapeutics and vaccines under federally mandated preparedness programs and in support of the pharmaceutical industry. Ghs conducts analysis programs for biological pathogens and supports test and evaluation of emerging biotechnologies and clinical diagnostics. Ghs conducts programs to assess agriculture products requiring registration under epa's requirements. Among ghs's largest clients are nih sponsored programs for niehs and nci. The focus of these research and development programs is chemical characterization, preparation of study articles and repository management to support toxicology and pre-clinical studies.”

“Other changes in net assets pension adjustment: $ ( 1,980,714) equity in earnings of alliance llc: 3,357,050 foreign currency exchange gain: 14,444 impairment loss ( 234,734) ----------- $ 1,156,046”